MAIA Biotechnology, Inc. (MAIA)
NYSEAMERICAN: MAIA · Real-Time Price · USD
1.410
+0.060 (4.44%)
Jun 26, 2026, 4:00 PM EDT - Market closed
MAIA Biotechnology Employees
MAIA Biotechnology had 13 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
13
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,865,274
Market Cap
85.73M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 13 | 0 | - |
| Dec 31, 2024 | 13 | 0 | - |
| Dec 31, 2023 | 13 | -5 | -27.78% |
| Dec 31, 2022 | 18 | 9 | 100.00% |
| Dec 31, 2021 | 9 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Champions Oncology | 213 |
| Adicet Bio | 102 |
| Cardiff Oncology | 31 |
| iBio, Inc. | 20 |
| Rallybio | 14 |
| Rein Therapeutics | 10 |
| Alterity Therapeutics | 9 |
| OS Therapies | 5 |
MAIA News
- 3 days ago - MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer - GlobeNewsWire
- 9 days ago - MAIA Biotechnology opens third clinical site in U.S. for Phase 2 THIO-101 trial - TheFly
- 10 days ago - MAIA Biotechnology Opens Enrollment for Phase 2 Expansion Trial of Novel Telomere-Targeting Agent at Winship Cancer Institute of Emory University - GlobeNewsWire
- 17 days ago - MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial - GlobeNewsWire
- 23 days ago - MAIA Biotechnology reports 29 patients dosed in Phase 3 THIO-104 trial - TheFly
- 23 days ago - MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial - GlobeNewsWire
- 24 days ago - MAIA Biotechnology receives FDA clearance for amendment to IND application - TheFly
- 24 days ago - MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion - GlobeNewsWire